World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

New Scientific Research Funding Available to Help Eliminate Pre-Term Deliveries from Preeclampsia

Cision PR Newswire by Cision PR Newswire
June 22, 2026
in Press Releases - Lifestyle
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

MELBOURNE, Fla., June 22, 2026 /PRNewswire/ — The Preeclampsia Foundation is seeking Letters of Intent for the Peter Joseph Pappas Research Grants funding program. The ultimate goal of this grant program is to drive research that will eliminate the delivery of pre-term babies as an intervention for severe preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy. Named for the infant son of preeclampsia survivor Lauren Pappas and her husband Clement, the program seeks to award multiple two-year grants in 2025 totaling up to $200,000.

Eligible applicants should focus on the current research gaps identified through a 2020 preeclampsia workshop jointly sponsored by the Preeclampsia Foundation and the Society for Maternal Fetal Medicine. Examples of such proposals include but are not limited to understanding pathophysiological pathways and subtypes of preeclampsia, mechanisms for improved diagnosis or prediction, therapeutic interventions to halt, reverse, or prevent the placental and organ dysfunction associated with the condition, and supporting preconception and inter-conception health to improve perinatal outcomes. In addition to meeting the fund’s research criteria, preference will be given to proposals that use or build upon data available through the Preeclampsia Registry™ (self-reported, whole exome sequenced, and clinical data), or that will produce data or biological materials that can be added to the Registry. All criteria are outlined in the application instructions, available at www.preeclampsia.org/research-funding.

The grant is named after the son of Lauren and Clement Pappas, who was delivered at 29-weeks due to severe preeclampsia and HELLP syndrome. The program has funded almost a dozen studies, including innovative research into potential therapeutics, genetic markers, and the role of placental functioning in preeclampsia’s development.

“We lost our son Peter due to preeclampsia following a 29-week delivery,” explained Lauren Pappas. “Since then, we have dedicated our lives to helping others avoid the same outcome by establishing the Peter Joseph Pappas Fund.”

“Thanks to generous contributions from family and friends, and our partnership with the Preeclampsia Foundation, we are making strides to reach our ultimate goal of eliminating pre-term births due to preeclampsia by 2050,” added Clement Pappas.

Complete details can be found online at www.preeclampsia.org/research-funding. Letters of intent are due by Friday, August 14, 2026, by 5:00 pm ET.

About the Preeclampsia Foundation

The Preeclampsia Foundation is a U.S.-based 501(c)(3) non-profit organization established in 2000 to improve the outcomes of hypertensive disorders of pregnancy by educating, supporting, and engaging the community, improving healthcare practices, and accelerating research. We envision a world where preeclampsia and related hypertensive disorders of pregnancy no longer threaten the lives of mothers and babies. For more information, visit www.preeclampsia.org.

About the Peter Joseph Pappas Research Grant Program
Clement and Lauren Pappas of Philadelphia, PA, lost their firstborn child, Peter Joseph, after HELLP syndrome necessitated his early delivery. The Pappas family, along with friends and family, have established this special fund with the Preeclampsia Foundation to advance research, with the overarching goal of eliminating pre-term births due to preeclampsia by 2050.

Contact: Danielle Babcock Sapienza
Preeclampsia Foundation
321.421.6957
417167@email4pr.com

Cision View original content:https://www.prnewswire.com/news-releases/new-scientific-research-funding-available-to-help-eliminate-pre-term-deliveries-from-preeclampsia-302804995.html

SOURCE Preeclampsia Foundation

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • Stark Future Closes Financing Round in Excess of €150 Million in Total Transactional Value as Its Electric Motorcycles Overtake Combustion on the World Stage

    0 shares
    Share 0 Tweet 0
  • TARSBOT and Aptiv Deepen Strategic Collaboration on Embodied AI

    0 shares
    Share 0 Tweet 0
  • Net Zero Will Cost Europe’s Largest Companies €60bn a Year in Carbon Removal, Senken’s Pace of Change 2026 Report Finds

    0 shares
    Share 0 Tweet 0
  • HKEX Launches Offshore RMB Bond Index

    0 shares
    Share 0 Tweet 0
  • Thunes Expands Real-Time Payouts to Bhutan, Unlocking the Nation’s Remittance Market

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler